new
   Indications for Enstilar
505
Nov 06, 2025

Enstilar is an innovative topical fixed-dose combination preparation that integrates the dual effects of a vitamin D analog and a corticosteroid, specifically designed for the treatment of plaque psoriasis.

Indications for Enstilar

Primary Target Population

Approved by the U.S. FDA, Enstilar is indicated for the topical treatment of plaque psoriasis in patients aged 12 years and older.

Through its unique mechanism of action, this medication significantly improves the symptoms of psoriatic lesions.

Applicable Disease Type

This product specifically targets the lesional areas of plaque psoriasis. With a once-daily administration regimen, it can effectively control disease progression.

Specifications and Physical Characteristics of Enstilar

Pharmaceutical Composition

Each gram of the foam contains 50 micrograms of calcipotriene (equivalent to 52.2 micrograms of calcipotriene monohydrate) and 0.643 milligrams of betamethasone dipropionate (equivalent to 0.5 milligrams of betamethasone).

The specification is labeled as 0.005%/0.064%, representing the precise concentration ratio of the active ingredients.

Description of Physical Properties

The product is a white to off-white opalescent liquid, stored in a pressurized aluminum spray can.

When applied, it appears as a white to off-white foam, which gradually collapses as the propellant evaporates.

Excipients and Propellants

The base contains white petrolatum, polyoxypropylene stearyl ether, mineral oil, racemic α-tocopherol, and butylated hydroxytoluene. Dimethyl ether and butane are used as propellants.

Storage and Handling Instructions for Enstilar

Temperature Control Requirements

The storage temperature should be maintained between 20°C-25°C (68°F-77°F), with an allowable fluctuation range of 15°C-30°C (59°F-86°F).

Safety Precautions

The container is a high-pressure product; piercing or incineration is strictly prohibited.

Avoid exposure to high-temperature environments or storage temperatures exceeding 120°F (49°C).

Strict Prohibition of Freezing Storage

Management of Usage Period: After opening the can, any unused product should be discarded within 6 months.

Special Usage Guidelines

The can must be shaken thoroughly before use.

The can may be held in any orientation for spraying, except horizontally.

Summary of Precautions

This product is flammable. Keep it away from heat sources and open flames during use, and smoking is prohibited.

Store it in a safe place out of the reach of children.

Pay attention to the expiration date of the product; use of expired products is strictly prohibited.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
How to relieve the side effects of Gilteritinib (Xospata)?

Side effect management of Lazertinib requires targeted measures based on specific reaction types, with key focus on...

Friday, February 13th, 2026, 11:29
What are the side effects of Gilteritinib (Xospata)?

Gilteritinib (Xospata) is a FLT3 inhibitor. Its adverse reactions mainly involve the hematological system,...

Friday, February 13th, 2026, 11:01
Where to Buy Venetoclax Tablets

Venetoclax is a targeted medication used for the treatment of chronic lymphocytic leukemia/small lymphocytic...

Thursday, February 12th, 2026, 13:49
Indications of Venetoclax Tablets

Venetoclax is an innovative BCL‑2 inhibitor that plays an important role in the treatment of hematologic...

Thursday, February 12th, 2026, 13:46
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved